- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02892331
Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans (HI-PACE)
The High Intensity Exercise to Promote Accelerated Improvements in CardiorEspiratory Fitness (HI-PACE) Study
Study Overview
Status
Conditions
Detailed Description
African Americans have a much greater risk of type 2 diabetes compared to Caucasians in the United States. Similarly, recent evidence has emerged that fitness level, a major risk factor for type 2 diabetes also tends to be lower in African Americans. Many scientific studies have shown that exercise training has a beneficial impact on fitness levels and a variety of other type 2 diabetes risk factors such as the reduction of glucose/insulin levels, and body fat Importantly, studies performed in mostly Caucasian populations suggest that exercise training at a vigorous intensity may promote greater improvements in type 2 diabetes risk factors compared to moderate intensity exercise, which may suggest that it has greater promise in reducing type 2 diabetes risk. However, few exercise training studies compare the health benefits of different exercise training programs (such as exercise intensity) in African Americans, which is clinically important due to their greater type 2 diabetes risk, and that fact that they are less likely to meet public health recommendations for physical activity compared to their Caucasian counterparts.
The High Intensity exercise to Promote Accelerated improvements in CardiorEspiratory fitness (HI-PACE) study will evaluate the effect of exercise intensity on cardiorespiratory fitness (CRF) and insulin sensitivity in obese (BMI: 30-45) African Americans (40-65 yrs.) with at least 1 additional T2D risk factor. Participants (n=60) will be recruited in collaboration with the ECU Center for Health Disparities, and subsequently randomized to moderate intensity (MOD-INT, n=20) or high intensity (HIGH-INT, n=20) aerobic exercise training, or to a control group (CON, n=20) for 24 weeks. Supervised exercise training will be performed at a heart rate associated with ~50% and ~75% of VO2 max in the MOD-INT and the HIGH-INT groups, respectively at the same exercise volume of 600 MET-minutes per week (consistent with public health recommendations). The primary outcome is the change in CRF, which will be assessed at baseline, mid-intervention, and follow-up. Insulin sensitivity will be measured via an intravenous glucose tolerance test at baseline and follow-up. Other secondary measures include mitochondrial oxidative capacity using infrared and measurements on muscle biopsies (PGC-1α and other indices of mitochondrial content), the expression of a protein involved with insulin action (GLUT-4 expression) in skeletal muscle as well as systemic inflammation, adiposity, quality of life and exercise enjoyment measures.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Damon L Swift, Ph.D.
- Phone Number: 252-737-1338
- Email: swiftd@ecu.edu
Study Contact Backup
- Name: Patricia Brophy, M.A.
- Phone Number: 252-737-1600
- Email: brophyp@ecu.edu
Study Locations
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- Recruiting
- East Carolina University
-
Contact:
- Damon L Swift, Ph.D.
- Phone Number: 252-737-1338
- Email: swiftd@ecu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- African American
- Body mass index 30-45 kg/m2
- sedentary/low active (step count ≤ 6,500 step/day)
- capable and willing to give written informed consent and understand exclusion criteria
- willingness to accept group assignment from randomization
- No resistance training and no structured aerobic exercise for > 20 minutes per day, 3+ days per week, for the last 6 months
- conditions that are contraindicated for exercise training
Exclusion Criteria:
- Resting blood pressure > 180 mm Hg systolic and/or >100 mm Hg diastolic; individuals on blood pressure medications meeting the blood pressure criteria are eligible
- Diagnosis of type 1 or 2 diabetes, and/or fasting glucose >125 mg/dL
- Medication for the treatment of type 1 or type 2 diabetes
- Bariatric surgery including gastric banding or bypass (potential effects on energy intake)
- Factors that may limit adherence to intervention or affect conduct of the trial
- Unable or unwilling to communicate with staff
- Failure to complete run-in or baseline testing
- Hospitalization for depression or severe mental illness in the last 6 months
- Not physically capable of performing the exercise required of the study protocol
- Consuming more than 14 alcoholic beverages per week
- Plan to be away from the Pitt County area more than 3 weeks in the next 3 months
- Lack support from a primary health care provider or family members
- Significant weight loss in the past year (> 20 pounds) or are currently using weight loss medications.
- Current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder
- Another member of the household who is currently a participant or staff member of this study
- Other temporary intervening event, such as sick spouse, or bereavement
- Other medical, psychiatric, or behavioral limitations that may interfere with study participation or the ability to follow the intervention protocol
- Underlying diseases or conditions likely to limit lifespan and/or affect the safety of the intervention
- Cancer requiring treatment in the past 5 years with anything but excellent prognosis
- Self-reported HIV, tuberculosis, Hepatitis B, or Hepatitis C
- History or evidence of serious arrhythmias, cardiomyopathy, congestive heart failure, aortic aneurism, myocardial infarction or heart transplantation
- Renal disease: urine protein > 100 mg/dl, serum creatinine ≥ 1.5 mg/dl or currently receiving dialysis.
- Auto-immune diseases (such as Lupus, Multiple Sclerosis, Graves' disease, or Rheumatoid arthritis)
- Chronic obstructive lung disease, peripheral vascular disease or angina that limits ability to follow exercise protocol
- History of stroke or transient ischemic attack
- History of vascular aneurysms
- History of bleeding disorders
- Pregnancy or plans to become pregnant
- Dieting or plans to diet, or in a weight loss program
- Any other medical condition or disease that is life threatening or that can interfere with or be aggravated by exercise.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control
This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
|
|
EXPERIMENTAL: MOD-INT
The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
|
Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max.
The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
|
EXPERIMENTAL: HIGH-INT
High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
|
Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment).
The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cardiorespiratory fitness
Time Frame: Baseline and 24 weeks
|
Fitness will be measured using a modified Balke protocol on a treadmill.
Participants will walk at an initial speed of 2.0 mph with 0% grade for the first 3 minutes after which the treadmill speed will increase to 3.0 mph for the next 3 minutes.
The treadmill grade will be increased by 2.5% every 3 minutes until volitional exhaustion.
Respiratory gases (VO2, CO2) and ventilation will be measured continuously using a True Max 2400 Metabolic Measurement Cart (Parvomedics, Salt Lake City Utah).
|
Baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body composition
Time Frame: Baseline and 24 weeks
|
Dual-energy X-ray absorptiometry will be used to measure changes in fat and lean mass.
|
Baseline and 24 weeks
|
Change in body weight
Time Frame: Baseline and 24 weeks
|
Weight will be measured using a calibrated scale
|
Baseline and 24 weeks
|
Change in waist circumference
Time Frame: Baseline and 24 weeks
|
Waist circumference will be measured at the natural waist (midway between the inferior border of the rib cage and the superior aspect of the iliac crest) with a Gulick tape measure.
Both landmarks (the inferior border of the ribcage and the superior aspect of the iliac crest) will be marked and the distance will be measured to determine the appropriate measurement site.
Staff will confirm that: 1) the measurement tape remains horizontal; 2) the tape touches the entire circumference of the participant; 3) abdominal tissue is not compressed; 3) the tape measure is not within abdominal folds; 4) the measurement is taken at the end of normal respiration.
The measurement will be repeated an additional time, and the reported value will be the average of these measurements.
Both measurements must be within 0.5 cm to be considered acceptable for data purposes.
|
Baseline and 24 weeks
|
Changes in physical activity levels
Time Frame: Baseline and 24 Weeks
|
Participants will wear an ActivPal accelerometer for seven consecutive days, 24-hrs/day.
The amount of time spent sitting and standing and steps will be calculated
|
Baseline and 24 Weeks
|
Change in dietary composition
Time Frame: Baseline and 24 weeks
|
Food Frequency Questionnaire (FFQ) contains approximately 105 items grouped by categories and is completed for both frequency of consumption as well as portion size selections by the individual.
The questionnaire, upon completion, provides estimated daily intake values for selected nutrients (kilocalories, macronutrients, and micronutrients) and provides information on food group servings.
|
Baseline and 24 weeks
|
Changes in blood lipids concentrations
Time Frame: Baseline and 24 weeks
|
Low density lipoproteins, high density lipoproteins, total cholesterol, and triglycerides will be measured from baseline and 24 weeks from blood samples by Labcorp Inc.
|
Baseline and 24 weeks
|
Change in systemic inflammation
Time Frame: Baseline and 24 weeks
|
High sensitivity c-reactive protein will be measured at baseline and follow-up
|
Baseline and 24 weeks
|
Change in insulin sensitivity
Time Frame: Baseline and 24 weeks
|
Insulin sensitivity will be measured using an intravenous glucose tolerance test
|
Baseline and 24 weeks
|
Change in arterial stiffness
Time Frame: Baseline and 24 weeks
|
Arterial stiffness will be measured using pulse wave velocity.
|
Baseline and 24 weeks
|
Change in quality of life
Time Frame: Baseline and 24 weeks
|
Quality of life (QOL) will be measured by the short form health survey (SF-36)
|
Baseline and 24 weeks
|
Change in mitochondrial enzymes and protein content
Time Frame: Baseline and 24 weeks
|
Mitochondrial enzymes (citrate synthase, COX IV, GLUT-4, CPT-1) protein content (COX IV, GLUT-4 CPT-1 and PGC-1 alpha)
|
Baseline and 24 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R03DK105297-01A1 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Moderate intensity exercise training (MOD-INT)
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPreDiabetes | AgingUnited States
-
Medical University of ViennaMedical Scientific Fund of the Mayor of Vienna; Austrian Heart FundsCompleted
-
University of Alabama at BirminghamSalk Institute for Biological Studies; Wright State UniversityCompleted
-
University of Central ArkansasCompletedType 2 DiabetesUnited States
-
Virginia Commonwealth UniversityRecruitingPeripheral Vascular DiseasesUnited States
-
Norwegian University of Science and TechnologyCompletedMyocardial Infarction | Heart FailureNorway
-
Peking University Third HospitalRecruitingObesity | Metabolic SyndromeChina
-
Yasemin ASLAN KELEŞIstanbul University - Cerrahpasa (IUC)CompletedEnd Stage Renal Disease | Exercise, CompulsiveTurkey
-
University of New BrunswickNew Brunswick Health Research FoundationCompleted
-
Arizona State UniversityMayo Clinic; University of AlbertaCompleted